BioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...
pharmaphorum3d
First Tysabri biosimilar cleared by FDA for MS
The main patents on Tysabri (natalizumab) expired in the US and Europe in February; although, various use patents claim protection until 2027 and are still in dispute. The green light from the FDA ...
pharmaphorum4d
AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease approval
It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...
Multiple Sclerosis News Today5d
Ocrevus, fampridine improve walking ability in MS: Review
Fampridine, which is approved to improve walking in MS patients, and Ocrevus may help ease walking impairments, a review of ...
Le Lézard2d
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
BioLineRx Ltd. , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December ...
C&EN5d
Dynamic Control to Maximize the Performance of Protein A Resin in Antibody Extraction
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Antibody therapies are critical in treating various diseases such as cancer and ...